TGFβRII modified NK Cell Development Service for Immune Reponse Improvement

Online Inquiry

Background Services Workflow Advantages FAQs Contact Us

Limited efficacy of current immunotherapies and NK cell suppression in challenging microenvironments are common challenges. Our TGFβRII-modified NK Cell Development Service significantly enhances immune response and overcomes resistance through advanced NK cell engineering and targeted TGFβRII modification.

Why We Need to Develop TGFβRII-modified NK Cells

The rapidly evolving field of gene therapy holds immense promise for treating complex diseases, particularly cancer. Natural Killer (NK) cells are pivotal components of the innate immune system, recognized for their potent anti-tumor and anti-viral capabilities. However, their therapeutic potential is frequently hampered by immunosuppressive factors within the disease microenvironment, notably transforming growth factor-beta (TGF-β). Research demonstrates that TGF-β profoundly inhibits NK cell proliferation, cytokine production, and cytotoxicity. This inhibition reduces the efficacy and duration of NK cell-based immunotherapies. Developing TGFβRII-modified NK cells is therefore crucial to bypass this resistance mechanism, unlocking their full therapeutic potential for robust immune response improvement.

Fig.1 TGF-β functions in cancer immune surveillance. (OA Literature) Fig.1 TGF-β plays a crucial role in cancer immune surveillance.¹

TGFβRII-modified NK Cell Development Service for Immune Response Improvement at Creative Biolabs

Creative Biolabs offers a comprehensive TGFβRII-modified NK cell development service designed to empower your immunotherapy projects with highly potent and resistant NK cell populations. We provide tailored solutions to enhance immune responses, particularly in challenging immunosuppressive environments.

Workflow: From Concept to Potent NK Cells

Step 1

NK Cell Isolation and Expansion

Highly pure NK cell populations are isolated from the provided source material using advanced cell separation techniques. These cells are then expanded ex vivo under optimized conditions to achieve sufficient cell numbers while maintaining their viability and functionality.

Step 2

TGFβRII Gene Modification

Utilizing state-of-the-art gene editing technologies (e.g., lentiviral transduction), the TGFβRII gene is precisely modified within the NK cells. This modification protects NK cells from TGF-β's immunosuppressive effects.

Step 3

Functional Validation and Characterization

Modified NK cells are subjected to thorough in vitro functional assessments. This includes cytotoxicity assays against target cells in the presence of TGF-β, cytokine production analysis (e.g., IFN-γ, TNF-α), proliferation assays, and phenotypic characterization (e.g., expression of activation markers, NK cell receptors).

Step 4

Quality Control and Purity Assessment

Strict quality control procedures are followed at every stage. This entails employing flow cytometry for sterility testing, mycoplasma identification, viability evaluation, and purity analysis of the finished cell product.

Step 5

Cryopreservation and Delivery

Upon successful completion of all stages, the modified NK cells are carefully cryopreserved using optimized protocols to maintain their integrity and functionality for long-term storage and shipment.

Our Service Highlights

Enhanced Efficacy: Overcome TGF-β-mediated immunosuppression, leading to superior NK cell activation and anti-tumor activity.
Improved Persistence: Modified NK cells exhibit better survival and sustained function in challenging microenvironments.
Broader Application: Applicable across various disease models, particularly those characterized by high TGF-β levels.
Reduced Resistance: Minimize immune evasion mechanisms employed by diseased cells, improving therapeutic outcomes.
Accelerated Research: Obtain ready-to-use, high-quality modified NK cells, saving significant time and resources in your laboratory.

FAQs

Q1: What are the typical applications of the TGFβRII-modified NK cells provided by Creative Biolabs?

A1: Our clients utilize these cells for a wide range of applications, including in vitro functional studies to understand immune evasion mechanisms, in vivopreclinical models for assessing therapeutic efficacy in immunosuppressive environments, and as a component for developing next-generation cell therapies. They are ideal for researchers seeking to overcome limitations of conventional NK cell therapies.

Q2: How does Creative Biolabs ensure the quality and functionality of the modified NK cells?

A2: We employ stringent quality control measures at every stage, from initial cell isolation to final cryopreservation. This includes comprehensive functional assays (cytotoxicity, cytokine production, proliferation), immunophenotyping, and sterility testing. Our detailed data reports provide full transparency into the quality and performance of your modified NK cells.

Q3: Can TGFβRII-modified NK cells be combined with other genetic modifications, such as CAR expression?

A3: Yes, our platform offers high flexibility. We can integrate TGFβRII modification with other genetic engineering strategies, including Chimeric Antigen Receptor (CAR) expression, to create multi-functional NK cells with enhanced targeting and resistance capabilities.

Related Services

To complement our TGFβRII-modified NK cell development service and further empower your research, Creative Biolabs offers a comprehensive suite of related services designed to enhance the functionality and applicability of your NK cell designs:

Work with Creative Biolabs

Creative Biolabs is committed to helping you make immunotherapy advancements more quickly. Our TGFβRII-modified NK Cell Development Service provides a powerful solution to enhance immune responses and overcome therapeutic challenges. Partner with us to leverage our scientific expertise and cutting-edge technology, driving your projects from discovery to successful application.

Reference

Xue, Vivian Weiwen et al. "Transforming Growth Factor-β: A Multifunctional Regulator of Cancer Immunity." Cancers vol. 12,11 3099. 23 Oct. 2020, doi:10.3390/cancers12113099. Distributed under Open Access License CC BY 4.0, without modification.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.